Published on 02/12/2025

Internal Peer Review Checklists for E&L Packages

The pharmaceutical industry faces stringent regulations around extractables and leachables (E&L) assessments to ensure product quality and patient safety. This step-by-step tutorial provides an in-depth guide to developing internal peer review checklists for E&L packages, emphasizing the significance of analytical evaluation thresholds (AET) and dose-based thresholds (DBT) for effective packaging qualification.

Understanding Extractables and Leachables in Pharmaceutical Packaging

Extractables and leachables represent compounds that may migrate from packaging materials into drug products, influenced by various factors such as temperature, time, and the nature of the drug. The regulatory bodies such as the FDA, European Medicines Agency (EMA), and Medicines and Healthcare products Regulatory Agency (MHRA) mandate rigorous evaluation of these compounds to mitigate risks associated with their presence in pharmaceutical formulations.

To ensure compliance and safeguard public health, pharmaceutical manufacturers must conduct comprehensive E&L studies as part of their packaging qualification processes. This involves multiple stages, including risk assessment, method development, testing, and documentation. Adherence to guidelines such as the PQRI guideline is crucial in achieving defensible results when submitting E&L packages for regulatory review.

Establishing Internal Peer Review Checklists

The creation of internal peer review checklists is pivotal for systematically evaluating E&L packages before they undergo regulatory scrutiny. This process enhances transparency, ensures thoroughness in assessments, and provides a documented basis for claims made in regulatory submissions.

Here are the key components to consider when developing these checklists:

• Template Design: Create an easy-to-use checklist template that allows reviewers to assess various aspects of E&L evaluations, ensuring it maintains clarity and responsiveness to stakeholder feedback.
• Criteria Selection: Define criteria that align with current regulations from entities such as ICH. Include specific requirements related to both AET and DBT interpretations for different products.
• Role Assignment: Clearly designate responsibilities among team members involved in reviewing E&L data and reports, ensuring accountability and expertise in each review process.

Step-by-Step Guide to Creating E&L Peer Review Checklists

Step 1: Define the Purpose and Scope of the Checklist

Determining the primary objectives of the internal peer review checklist is essential for achieving focused and effective reviews. Consider factors such as:

• The types of products being evaluated (e.g., injectables, biologics).
• The stage of development during which the checklist will be applied.
• Specific risks associated with E&L for each product category.

Step 2: Align with Regulatory Requirements

Consult applicable guidelines from the FDA or EU GMP Annex 1 to align your checklist criteria with mandated practices. Both US and European regulations stress the importance of maintaining container closure integrity (CCI) and conducting risk assessments tailored to E&L evaluations. Understanding the expectations from a regulatory perspective ensures your checklist appropriately reflects compliance standards.

Step 3: Develop Checklist Items

Checklist items should encompass a detailed examination of various E&L aspects, including but not limited to:

• Raw material characterization (e.g., compositions, suppliers).
• Methodology for E&L extraction studies.
• Analysis of identified compounds and their respective concentrations.
• Assurances of methodological validity and reliability (e.g., compliance with USP).

Step 4: Incorporate AET and DBT Calculations

A critical aspect of E&L compliance is the establishment of analytical evaluation thresholds (AET) and dose-based thresholds (DBT). Include specific checklist items related to:

• The calculation methodologies for determining AET and DBT.
• Documentation of statistical analyses supporting threshold establishment.
• Rationale for any deviations from standard thresholds, if applicable.

Step 5: Review and Test the Checklist

Conduct an initial review of the checklist with cross-functional stakeholders to gather feedback on its effectiveness and user-friendliness. Pilot the checklist using a small number of E&L packages to evaluate its practicality and completeness.

Step 6: Implement and Train Staff

Once finalized, integrate the checklists into your E&L validation processes. Provide thorough training for all personnel involved in E&L assessments to ensure they understand how to use the checklist effectively.

Step 7: Continuous Improvement and Update

Establish a routine schedule for reviewing and updating the checklists based on emerging regulatory changes, advances in analytical techniques, and company-specific experiences. This practice ensures your checklists remain relevant and compliant.

Conducting E&L Risk Assessments

Parallel to developing internal checklists, performing comprehensive E&L risk assessments is fundamental for determining the potential impact of extractables and leachables on product quality and patient safety. Risk assessment methodologies involve critical evaluation of materials, processing conditions, and drug formulation attributes.

Understanding Risk Assessment Methodologies

Utilize a systematic approach following the principles outlined in the ICH guidelines and incorporate aspects such as:

• Material Risk: Analyze the inherent risk posed by the packaging materials used, considering the likelihood of leachables’ release.
• Product Risk: Assess how the drug formulation may interact with packaging components under various conditions.
• Mitigation Strategies: Identify strategies to minimize risks, such as selecting materials with a lower likelihood of extractables.

Integrating Risk Assessment with E&L Testing

Integrate findings from risk assessments into your E&L testing protocols. Risk stratification can guide the depth and breadth of E&L evaluations performed on different products, promoting risk-based decision-making.

Documentation and Filing for Regulatory Submission

Documentation represents a critical component throughout the E&L evaluation process. Each checklist completion should result in comprehensive records outlining findings, methodologies, and justifications for decisions made during the review. This documentation is essential when preparing submissions to regulatory agencies.

Preparation of Regulatory Submissions

When compiling E&L packages for regulatory submission, ensure that your documentation includes:

• A comprehensive report summarizing the E&L studies, including methodologies, results, and conclusions about product safety.
• A well-organized representation of the internal peer review checklist findings that provides transparency into the review process.
• Supporting data for AET and DBT calculations, including raw data and any relevant analyses.

Post-Submission Activities

After submission, be prepared for potential inquiries from regulatory bodies. Establish a robust response strategy that allows for quick retrieval of necessary documentation and clarifies any points raised during the review of your E&L submission.

Conclusion

Developing internal peer review checklists for extractables and leachables packages is vital for maintaining regulatory compliance and ensuring product safety. Emphasizing rigorous evaluation practices surrounding AET, DBT, and CCI not only enhances the defensibility of your submissions but also fosters a culture of continuous improvement in pharmaceuticals. By adhering to the outlined procedures, pharmaceutical professionals can position themselves to meet regulatory demands effectively while prioritizing patient safety.